A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

NCT02148861 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin icodec
DRUG: insulin degludec
DRUG: placebo

Sponsor

Novo Nordisk A/S